Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
ID:
Password:
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

Agents/Distributors
 Regional Subscription Agents/Distributors
 
Current Topics in Virology   Volumes    Volume 12 
Abstract
Increasing the immunogenicity of HIV and influenza virus vaccines by anti-Gal mediated targeting to antigen presenting cells
Uri Galili
Pages: 1 - 12
Number of pages: 12
Current Topics in Virology
Volume 12 

Copyright © 2014 Research Trends. All rights reserved

ABSTRACT
 
Immunogenicity of suboptimal viral vaccines is increased by targeting vaccines to antigen presenting cells (APC) for effective uptake, using the natural anti-Gal antibody which constitutes 1% of immunoglobulins in humans. Anti-Gal interacts with “α-gal epitopes” (Galα1-3Galβ1-4GlcNAc-R) which can be synthesized on viral glycoproteins by recombinant α1,3galactosyltransferase (α1,3GT). Viral vaccines carrying α-gal epitopes form in situ immune complexes with anti-Gal. The immunocomplexed antibody binds via its Fc portion to Fcγ receptors on APC and induces uptake of the vaccine, which is much higher than the physiologic uptake by APC via random endocytosis. Studies on increased immunogenicity of viral vaccines were performed in the experimental model of α1,3GT knockout mice which produce anti-Gal. Recombinant gp120 of HIV and inactivated influenza virus, both engineered to carry α-gal epitopes, were studied as vaccines. The increased uptake of these vaccines resulted in effective processing and presentation of their immunogenic peptides and induction of 10 to 100-fold higher T and B cell responses in comparison to vaccines lacking α-gal epitopes. The studies with vaccinating influenza virus carrying α-gal epitopes further demonstrated ~10-fold increased resistance to challenge with live virus in comparison to mice immunized with virus lacking this epitope. Virus matrix or core proteins lacking carbohydrate chains also can be targeted by anti-Gal to APC by producing them as fusion proteins with envelope glycoproteins engineered to carry α-gal epitopes. Thus, fusion of HIV core protein p24 with gp120, followed by synthesis of α-gal epitopes on carbohydrate chains of the fusion product markedly increased immunogenicity of p24. Synthesis of α-gal epitopes on viral vaccines may also be achieved by an intracellular pathway in cell lines that contain several α1,3GT transgene copies. The high activity of α1,3GT within these cells results in synthesis of multiple α-gal epitopes on propagated viruses or on viral glycoproteins produced in such cell lines.
Buy this Article


 
search


E-Commerce
Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Login
Search Products
Browse in Alphabetical Order : Journals
Series/Books
Browse by Subject Classification : Journals
Series/Books

Miscellaneous
Ordering Information Ordering Information
Downloadable forms Downloadable Forms